Chronic Rhinosinusitis Trial, Completed NCT02927834 Sponsor: Loma Linda University Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people across three groups — eight in each group. The three groups were: those who received an antibiotic only, those who received the antibiotic Augmentin combined with a 6-day course of steroids, and those who received Augmentin combined with a 21-day course of steroids. The trial was measuring sinus and nasal symptoms using three tools: a symptom questionnaire (called the SNOT-20), a physical examination of the nasal cavity using a small camera (nasal endoscopy), and a CT scan of the sinuses. By the end of the study, 7 people completed the antibiotic-only group, and 6 people completed each of the two Augmentin-with-steroid groups. The reported data shows the following scores at the end of the trial. For the SNOT-20 symptom questionnaire (scored 0–100, where a lower number means fewer symptoms reported): the antibiotic-only group scored 50.33, the Augmentin with 6-day steroid group scored 53.14, and the Augmentin with 21-day steroid group scored 37. For the nasal camera examination (scored 0–12, lower is better): the scores were 2.55, 3.00, and 2.16 respectively across the three groups. For the CT scan of the sinuses (scored 0–20, lower is better): the scores were 10.33, 11.00, and 11.83 respectively. It is worth noting that the trial enrolled only a small number of people — around six to eight per group — which is important context when looking at these numbers. No data about the statistical significance of any differences between the groups (that is, whether the differences seen were likely due to chance or not) was included in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Chronic Rhinosinusitis Trial, Completed

NCT02927834
Completed Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had ongoing sinus symptoms for at least 3 months that meet the recognized definition of chronic rhinosinusitis.
  • You have had a CT scan of your sinuses (either done at the clinic or taken within the last 3 weeks) showing a moderate or higher level of sinus disease, based on a standard scoring system called the Lund-Mackay score of 6 or above.
  • You do not have nasal polyps (small growths inside the nose), as confirmed by a camera examination of your nose at the clinic.
  • You are willing to take part in a clinical research study.
  • You are between 18 and 80 years old.

Who may not be able to join:

  • You have a medical condition that means you cannot safely take steroid medications, such as diabetes.
  • You are unable or unwilling to take the antibiotics or steroids that are part of the study treatment.
  • You have already been treated with antibiotics and/or steroid tablets or injections for more than 3 weeks for this condition.
  • You have a specific type of chronic sinus condition known to be very difficult to treat with medication, such as Wegener's granulomatosis, primary ciliary dyskinesia, or sarcoidosis.
  • Your sinus problems are caused by a previous surgery, a dental procedure, or an unusual structure in your nose or sinuses.
  • You have nasal polyps found during a physical examination of your nose.
  • You are currently pregnant or may possibly be pregnant.
  • Your CT scan shows a Lund-Mackay score below 6, meaning the sinus disease is considered less than moderate.
  • You are younger than 18 or older than 80 years old.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Loma Linda University
Registry
ClinicalTrials.gov
Start date
1 August 2015
Est. completion
1 December 2018

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sinonasal Outcome Test (SNOT 20); Nasal Endoscopy; CT Scan Changes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov